AACR 2025
GemPharmatech is excited to be attending the AACR Annual Meeting 2025, where we will be showcasing our latest innovations in preclinical oncology research. As a trusted partner to drug developers worldwide, we offer the world’s largest repository of genetically engineered mouse models—more than 25,000 strains—generated to-date. From T cell engagers and CAR-T therapies to resistance modeling and tumor vaccine development, our models are designed to support your preclinical oncology pipeline and reduce translational risk.
Heading to AACR 2025? Let’s connect!
Visit our booth, explore our nine featured posters, and meet with our expert team to discuss how we can help drive your next scientific breakthrough. Book a meeting in advance to secure time with us and learn how GemPharmatech can empower your research and development goals.
SCHEDULE A MEETING WITH OUR TEAM
Explore Our Posters
Our nine poster presentations showcase some of our latest R&D data and cutting-edge research. If you’re interested in learning more, please book a meeting with us to dive deeper into the details.
▎Monday, April 28, 2025
09:00 AM - 12:00 PM | Section 20 | Board 15
Poster #1714: Understanding Antibody Drug Conjugate (ADC) Resistance Using Preclinical Enhertu-Induced Resistant Models
09:00 AM - 12:00 PM | Section 3 | Board 29
Poster #1296: Development of a Novel NCG-hIL15-FcγR-KO Model for Precise Drug Efficacy Evaluation
09:00 AM - 12:00 PM | Section 3 | Board 30
Poster #1297: Novel Mouse Models to Study Bone and Brain Metastasis
02:00 PM - 05:00 PM | Section 39 | Board 8
Poster #3532: Development of Mouse Models for Preclinical Evaluation of Cancer mRNA Vaccines
▎Tuesday, April 29, 2025
09:00 AM - 12:00 PM | Section 4 | Board 23
Poster #3930: Preclinical Models of Cancer Cachexia: Bridging the Gap to Clinical Applications
02:00 PM - 05:00 PM | Section 18 | Board 18
Poster #5556: Development of Osimertinib Resistant Mouse Models for Preclinical Evaluation of Third-Generation EFGR-TKI Therapies
02:00 PM - 05:00 PM | Section 38 | Board 25
Poster #6117: Development of Preclinical Models for the Evaluation of Conventional and In Vivo CAR-T Therapies
▎Wednesday, April 30, 2025
09:00 AM - 12:00 PM | Section 38 | Board 1
Poster 7254: Mouse Models for Alleviating GvHD and Assessing On-Target Off-Tumor Toxicity of Bispecific T-Cell Engagers
09:00 AM - 12:00 PM | Section 38 | Board 2
Poster 7255: Novel Anti-PD(L)1 Resistance Models for Post-Anti-PD(L)1 Drug Development
Advance Your Oncology Research with GemPharmatech’s Industry-Leading Mouse Models
Our oncology-focused platforms support key areas including:
Immuno-oncology: Over 800+ humanized target models including PBMC/HSC-NCG for immune checkpoint blockade evaluation, plus specialized models for CD3 T cell engagers and γδT cell therapies.
CAR-T and NK therapies: Flexible in vivo models such as NCG, NCG-MHCI/II-DKO, and cytokine-enhanced systems (huIL2/IL15) for precise evaluation of CAR-T, CAR-NK, and CAR-M therapies.
Metastasis and resistance modeling: Advanced CDX, syngeneic, and spontaneous tumor models, including anti-PD1 and ADC resistance models to help investigate therapeutic efficacy and overcome resistance mechanisms.
ADC, cytokine, and vaccine evaluation: Reliable platforms for ADC and cytokine drug testing, along with HLA humanized models for tumor vaccine studies.
Safety and efficacy studies: Tailored humanized models for safety profiling of novel targets (e.g., PD1, PDL1, GARP), along with robust tools for ADCC/NK cell targeting and myeloid-targeting agents.
From early-stage discovery to preclinical validation, GemPharmatech’s models deliver the translational power to move your cancer therapies forward—faster.
Learn More and Stay Ahead
Explore our latest resources designed to help oncology researchers optimize study design, reduce translational risks, and accelerate time to clinic.
On-Demand Webinar:
Developing Robust Preclinical Evaluation Strategies for T-Cell Engagers (TCEs): Accelerating Development and Reducing Translational Risks
Gain actionable insights into preclinical strategies for evaluating TCEs, including model selection, efficacy readouts, and managing safety assessments. This webinar highlights how GemPharmatech’s advanced humanized mouse models, including CD3E knock-in and PBMC-engrafted platforms, are used to streamline TCE development while improving clinical predictability.
Blog:
Accelerating TCE Drug Development with Humanized Mouse Models
Learn how humanized mouse models are transforming TCE research by enabling accurate assessment of T cell activation, cytokine release, and anti-tumor efficacy. This article highlights model selection criteria, translational challenges, and how to mitigate them with GemPharmatech’s tailored solutions.
Blog:
Mouse Models for Studying Anti-PD-1 Resistance
Explore the mechanisms behind anti-PD-1 therapy resistance and how specialized mouse models—including syngeneic models with induced resistance and B2M-null mutations—can help unravel resistance pathways and guide the development of next-generation immunotherapies.
Ready to Accelerate Your Pipeline?
Navigating the world’s largest repository of more than 25,000 genetically engineered mouse models can be challenging—let us guide you! Schedule a meeting with us at AACR to discuss how GemPharmatech can help you find the right mouse strain to support your project needs and drive your research forward.